Repositioning Candidate Details
| Candidate ID: | R1570 |
| Source ID: | DB15719 |
| Source Type: | approved |
| Compound Type: | biotech |
| Compound Name: | Belantamab mafodotin |
| Synonyms: | Belantamab mafodotin; Belantamab Mafodotin-blmf |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | Belantamab mafodotin, or GSK2857916, is an afucosylated monoclonal antibody that targets B cell maturation antigen conjugated to the microtubule distrupter monomethyl auristatin-F (MMAF). Belantamab mafodotin was granted FDA approval on 5 August 2020. |
| CAS Number: | 2050232-20-5 |
| Molecular Weight: | |
| DrugBank Indication: | Belantamab mafodotin is indicated in the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. |
| DrugBank Pharmacology: | Belantamab mafodotin treats multiple myeloma through antibody dependant cell mediated cytotoxicity as well as G2/M cell cycle arrest. It has a narrow therapeutic index due to the incidence of adverse effects, and a long duration of action as it is given every 3 weeks. Patients should be counselled regarding the risk of keratopathy. |
| DrugBank MoA: | Belantamab mafodotin, or GSK2857916, is an afucosylated monoclonal antibody that targets B cell maturation antigen (BCMA) conjugated to the microtubule distrupter monomethyl auristatin-F (MMAF). Afucosylation of the Fc region of monoclonal antibodies enhances binding to the Fc region, which enhances antibody dependant cell mediated cytoxicity. BCMA is uniquely expressed on CD138-positive myeloma cells. Targeting BCMA allows belantamab mafodotin to be highly selective in its delivery of MMAF to multiple myeloma cells. Belantamab mafodotin binds to BCMA, is internalised into cells, and releases MMAF. The MMAF payload binds to tubulin, stopping the cell cycle at the DNA damage checkpoint between the G2 and M phases, resulting in apoptosis. |
| Targets: | Tumor necrosis factor receptor superfamily member 17 binder |
| Inclusion Criteria: | Therapeutic strategy associated |
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|